Latest News

INTERVENTIONAL
POSTED BY CARA SCHILLINGER ON 10/3/2012

Health Canada Approves Esbriet® as First Treatment for Fatal Lung Disease


- Novel oral therapy slows progression of IPF in mild to moderate patients -
- Esbriet expected to be available on January 1, 2013 -
- Company to provide more details on third quarter earnings call -

INTERVENTIONAL
POSTED BY CARA SCHILLINGER ON 9/24/2012

Recruitment complete for two pivotal Phase III studies of nintedanib* in patients with idiopathic pulmonary fibrosis

24th September 2012 13:16 IST
Ingelheim, Germany (Business Wire (Business Wire India))

For NON-U.S Health Media Only

INTERVENTIONAL
POSTED BY CARA SCHILLINGER ON 9/20/2012

Thalidomide Eases Cough in Lung Fibrosis Patients

INTERVENTIONAL
POSTED BY CARA SCHILLINGER ON 9/10/2012

FIBROGEN ANNOUNCES PRESENTATION OF UPDATED RESULTS AT EUROPEAN RESPIRATORY SOCIETY ANNUAL CONGRESS

San Francisco, CA - September 5, 2012

INTERVENTIONAL
POSTED BY CARA SCHILLINGER ON 9/4/2012

InterMune Reports New Analyses from the RECAP Study of EsbrietĀ® (pirfenidone) at ERS

INTERVENTIONAL
POSTED BY CARA SCHILLINGER ON 7/9/2012

A Placebo-Controlled Randomized Trial of Warfarin in
Idiopathic Pulmonary Fibrosis

Imre Noth1, Kevin J. Anstrom2, Sara Bristol Calvert2, Joao de Andrade3, Kevin R. Flaherty4,